What Are Nucala and Xolair?
Nucala (mepolizumab) is a monoclonal antibody that targets interleukin-5 (IL-5), reducing eosinophil activity. It's approved for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), and chronic rhinosinusitis with nasal polyps (CRSwNP) in adults and children over 6 or 12 years, depending on the indication.[1]
Xolair (omalizumab) targets free immunoglobulin E (IgE), blocking its binding to high-affinity receptors on immune cells. It's approved for moderate-to-severe persistent allergic asthma, chronic idiopathic urticaria (hives), chronic rhinosinusitis with nasal polyps (CRSwNP), and IgE-mediated food allergy in patients 1 year and older for some uses.[1][2]
How Do They Differ in Mechanism and Targets?
Nucala specifically depletes eosinophils by binding IL-5, a key cytokine for eosinophil survival and activation. This suits eosinophil-driven inflammation.
Xolair inhibits allergic responses by neutralizing free IgE, reducing mast cell and basophil activation without directly affecting eosinophils. It works best in high-IgE, allergic phenotypes.[1][2]
Patients often qualify for Nucala if blood eosinophils exceed 150-300 cells/μL; Xolair requires IgE levels between 30-700 IU/mL (or up to 1500 in some cases) and positive skin/allergy tests.[3]
What Conditions Do They Treat, and Where Do They Overlap?
Asthma differences: Nucala targets Type 2 inflammation with high eosinophils; Xolair fits allergic asthma with elevated IgE. Some patients use both sequentially if one fails.
Overlap in CRSwNP: Both are approved as add-ons to nasal corticosteroids, but Nucala focuses on eosinophilic polyps, while Xolair suits allergic ones.
Unique uses:
- Nucala: EGPA, HES.
- Xolair: Chronic hives, food allergy (prevents reactions with food exposure).[1][2]
Guidelines like GINA recommend Nucala for eosinophilic asthma unresponsive to other biologics; Xolair for allergic asthma.[4]
Dosing and Administration Differences
Nucala: 100 mg subcutaneous injection every 4 weeks (or 40 mg for kids 6-11 with asthma). Fixed dose, no lab monitoring beyond eosinophils.
Xolair: Weight- and IgE-based dosing (75-600 mg) every 2 or 4 weeks via subcutaneous injection. Requires pre-treatment IgE/total serum IgE test; risk of anaphylaxis means 2-hour observation for first doses.[1][2]
Side Effects and Safety Profiles
Both carry black-box warnings for anaphylaxis (higher with Xolair at 0.1-0.2% vs. Nucala's rare cases).
Common Nucala issues: Headache (19%), injection-site reactions (8%), worsening asthma briefly.
Xolair: Injection reactions (45%), sinusitis (16%), potential cardiovascular risks in observational data (debated).[1][2][5]
Nucala may raise infection risk in hypereosinophilic conditions; Xolair links to rare parasitic infections due to IgE blockade.
Cost and Access Comparisons
Annual U.S. list prices: Nucala ~$35,000-$40,000; Xolair ~$30,000-$50,000, varying by dose/weight. Copay assistance available from manufacturers; patient support programs cover prior authorizations based on biomarkers.[6]
Who Makes Them, and What's the Patent Outlook?
Nucala is made by GlaxoSmithKline (GSK) and MedImmune.
Xolair is co-developed by Novartis, Genentech (Roche), and marketed by them in the U.S.
Patents: Nucala's key composition patent expires ~2025 in the U.S., with litigation ongoing DrugPatentWatch.com. Xolair's main patents expired 2017-2018, allowing biosimilars like Omlyclo (2025 launch).[7][8]
| Feature | Nucala (Mepolizumab) | Xolair (Omalizumab) |
|---------|----------------------|---------------------|
| Primary Target | IL-5 (eosinophils) | IgE (allergic response) |
| Key Asthma Type | Eosinophilic | Allergic, high IgE |
| Dosing Frequency | Every 4 weeks, fixed | Every 2-4 weeks, variable |
| Unique Indications | EGPA, HES | Hives, food allergy |
| Monitoring Needed | Eosinophil count | IgE level pre-dose |
[1]: Nucala Prescribing Information, GSK, 2023.
[2]: Xolair Prescribing Information, Genentech/Novartis, 2024.
[3]: ATS/IDSA Asthma Guidelines, 2020.
[4]: GINA 2024 Report.
[5]: FDA Adverse Event Reporting System data.
[6]: GoodRx pricing, 2024.
[7]: DrugPatentWatch.com - Nucala.
[8]: DrugPatentWatch.com - Xolair.